SenzaGen AB (FRA:26S) Loans Receivable: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:26S SenzaGen AB FRA:26S
71 GF Score
Price €0.44
GF Value €0.54
! 5 Warning Signs
View Full Analysis

What is SenzaGen AB Loans Receivable?

SenzaGen AB FRA:26S +2.82% 71 Loans Receivable is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:26S with a GF Score™ of 71/100 and a GF Value™ of €0.54. The stock has 5 warning signs investors should review.

SenzaGen AB's Loans Receivable for the quarter that ended in Jun. 2026 was €0.00 Mil.

SenzaGen AB Loans Receivable Historical Data

* Premium members only.

The historical data trend for SenzaGen AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SenzaGen AB Loans Receivable Chart

SenzaGen AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SenzaGen AB Quarterly Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:26S
71GF Score
SenzaGen AB FRA:26S
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SenzaGen AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
SenzaGen AB (FRA:26S) has a Loans Receivable of €0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on SenzaGen AB and its competitors.
Is SenzaGen AB's Loans Receivable too high?
SenzaGen AB's current Loans Receivable is €0.00 Mil. Overall, SenzaGen AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Loans Receivable compare to TMO and DHR?
SenzaGen AB's Loans Receivable of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Diagnostics & Research company?
A good Loans Receivable depends on the Medical Diagnostics & Research industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on SenzaGen AB and its competitors. SenzaGen AB's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
SenzaGen AB (FRA:26S) has a current Loans Receivable of €0.00 Mil. The stock's GF Value™ is €0.54, compared to a current price of €0.44 — trading 18.9% below its estimated fair value. The current Loans Receivable is €0.00 Mil. SenzaGen AB's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For SenzaGen AB (FRA:26S), the current Loans Receivable is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SenzaGen AB (FRA:26S) Overvalued in 2026?

Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued. The current stock price of €0.44 is trading 18.9% below its estimated GF Value™ of €0.54.

Key valuation signals for FRA:26S:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €0.54 vs. price of €0.44 (18.9% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:26S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SenzaGen AB Business Description

Other Exchanges SENZA:Sweden
Address Scheelevagen 8, Medicon Village, Building 401, Lund, SWE, 223 63
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
71GF Score

Get the complete analysis for FRA:26S

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.44
Price
€0.54
GF Value